Provided by Tiger Trade Technology Pte. Ltd.

Theravance Biopharma

17.03
-0.0100-0.06%
Volume:870.66K
Turnover:14.84M
Market Cap:882.64M
PE:16.30
High:17.08
Open:17.08
Low:17.02
Close:17.04
52wk High:21.03
52wk Low:13.08
Shares:51.83M
Float Shares:25.86M
Volume Ratio:2.41
T/O Rate:3.37%
Dividend:- -
Dividend Rate:- -
EPS(TTM):1.05
EPS(LYR):2.06
ROE:20.91%
ROA:1.33%
PB:3.05
PE(LYR):8.27

Loading ...

Theravance Biopharma Inc: Expects to Incur About $5 to $7 Million in One-Time Cash Severance Costs Related to Restructuring Actions

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Restructuring Will Involve Winding Down R&D Function and Significantly Reducing G&a Function

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc - Strategic Review Committee Actively Evaluating Opportunities to Maximize Shareholder Value

THOMSON REUTERS
·
May 07

Theravance Biopharma Q1 Net Income USD -4.933 Million

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Implementing an Organizational Restructuring to Streamline Costs and Align Its Resources

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Restructuring Is Expected to Reduce Operating Expenses by About 60%

THOMSON REUTERS
·
May 07

Theravance Biopharma Inc: Restructuring Actions Expected to Be Implemented Over Next 2 Quarters

THOMSON REUTERS
·
May 07

Theravance Biopharma announces annual general meeting

Reuters
·
Apr 29

Theravance Biopharma Is Maintained at Neutral by B. Riley Securities

Dow Jones
·
Apr 08

B. Riley Raises Price Target on Theravance Biopharma to $17 From $14, Keeps Neutral Rating

MT Newswires Live
·
Apr 07

Theravance Secures Long-Term YUPELRI Patent Litigation Settlement

TIPRANKS
·
Mar 31

Theravance Biopharma Inc -Co's Units and Mylan Enter Settlement Agreement With Mankind on Yupelri Litigation - SEC Filing

THOMSON REUTERS
·
Mar 31

Theravance Biopharma: Theravance & Mylan Granted Mankind License to Market Generic Yupelri in U.S. on or After April 23, 2039

THOMSON REUTERS
·
Mar 31

Theravance Biopharma Inc - Settlement Subject to Review by U.S. Department of Justice and Federal Trade Commission - SEC Filing

THOMSON REUTERS
·
Mar 31

Theravance, Viatris settle Yupelri patent suit, allow Mankind generic launch in 2039

Reuters
·
Mar 31

Theravance Biopharma Is Maintained at Hold by TD Cowen

Dow Jones
·
Mar 23

Theravance Biopharma price target raised to $15 from $13 at TD Cowen

TIPRANKS
·
Mar 23

Theravance Biopharma: Post‑CYPRESS Restructuring Leaves Limited Upside and Justifies Neutral Stance

TIPRANKS
·
Mar 23

Theravance Biopharma Price Target Maintained With a $21.00/Share by BTIG

Dow Jones
·
Mar 20

Theravance Biopharma investors face litigation after 26% stock plunge

Reuters
·
Mar 19